A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Alessia GarufiSilvia BaldariRiccardo PettinariMaria Saveria Gilardini MontaniValerio D'OraziGiuseppa PistrittoAlessandra CrispiniEugenia GiornoGabriele ToiettaFabio MarchettiMara CironeGabriella D'OraziPublished in: Journal of experimental & clinical cancer research : CR (2020)
These findings underline the prosurvival role of curcumin-induced NRF2 expression in cancer cells even when cells underwent mutp53 downregulation and/or wtp53 activation. Thus, NRF2 inhibition increased cell demise particularly in cancer cells carrying p53 either wild-type or mutant suggesting that p53 is crucial for efficient cancer cell death. These results may represent a paradigm for better understanding the cancer cell response to therapies in order to design more efficient combined anticancer therapies targeting both NRF2 and p53.